HONEUR Haematology Outcomes Network Europe Janssenled initiative collaboration Rather creating central data repository HONEUR federated data network enables partner keep full control data analysis bringing together data centre Europe scale research haematological malignancies aspires create future patient haematological malignancy across Europe improved outcome power RealWorld Data RealWorld Evidence maximised HONEUR created secure collaborative platform enables partnering data centre across Europe including Janssen liberate transformational potential RealWorld Evidence use holistic approach combining technology data science able analyse data hospitals registry sources HONEUR portal core network secured environment accessible HONEUR partners offer different functionality partners data catalogue contains description various data set data partner engage them study catalogue central place study request get initiated analysis script eventually aggregated result stored visible study participant only patientlevel data stored HONEUR portal aggregated result research question CDM  OMOP Navigation Home Accelerated realworld data analysis evidence sharing Federated network connectivity data always stay local HONEUR Treating patient haematological malignancy ha progressed significantly recent years extensive scientific research still needed Fortunately huge untapped resource help RealWorld Data RWD Janssen believe RWD ha transformational potential help u develop new tool evidencebased therapies evolve diseasecentred patientcentred model healthcare widespread acceptance usage RWD one key driver moving valuebased healthcare system Valuebased healthcare seek better population health outcome improved patient experiences promoting sustainability increased efficiency reduced health spending overall Better collaboration key unlocking RWDs potential uniting data partners leveraging complementary strengths standardising data common data model end HONEUR Haematological Outcomes Network Europe wa created increase knowledge understanding haematological malignancy improve outcome patient across Europe invite join HONEUR become part federated network collaborating unlock transformational potential RealWorld Data RWD Together help create faster efficient European research environment better share manages RealWorld Evidence RWE generated RWD mission HONEUR created secure collaborative platform enables partnering data centre across Europe including Janssen liberate transformational potential RealWorld Evidence approach use holistic approach combining technology data science able analyse data hospitals registry sources Welcome HONEUR HONEUR PHDENPR Data partner benefit Collaboration full data control data always stay local Strengthened ability perform high quality research part federated network Compensation effort based Fair Market Value Increased data value via expanded authorship publication possibility sponsored study Access  data set patient MMCLLAML Participation network pioneering data management analysis Improved understanding patient treated real world ITEM CODE RF  DATE PREPARATION JANUARY  HONEUR Network Data Partners Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation Home Accelerated realworld data analysis evidence sharing Federated network connectivity data always stay local HONEUR Treating patient haematological malignancy ha progressed significantly recent years extensive scientific research still needed Fortunately huge untapped resource help RealWorld Data RWD Janssen believe RWD ha transformational potential help u develop new tool evidencebased therapies evolve diseasecentred patientcentred model healthcare widespread acceptance usage RWD one key driver moving valuebased healthcare system Valuebased healthcare seek better population health outcome improved patient experiences promoting sustainability increased efficiency reduced health spending overall Better collaboration key unlocking RWDs potential uniting data partners leveraging complementary strengths standardising data common data model end HONEUR Haematological Outcomes Network Europe wa created increase knowledge understanding haematological malignancy improve outcome patient across Europe invite join HONEUR become part federated network collaborating unlock transformational potential RealWorld Data RWD Together help create faster efficient European research environment better share manages RealWorld Evidence RWE generated RWD mission HONEUR created secure collaborative platform enables partnering data centre across Europe including Janssen liberate transformational potential RealWorld Evidence approach use holistic approach combining technology data science able analyse data hospitals registry sources Welcome HONEUR HONEUR PHDENPR Data partner benefit Collaboration full data control data always stay local Strengthened ability perform high quality research part federated network Compensation effort based Fair Market Value Increased data value via expanded authorship publication possibility sponsored study Access  data set patient MMCLLAML Participation network pioneering data management analysis Improved understanding patient treated real world ITEM CODE RF  DATE PREPARATION JANUARY  HONEUR Network Data Partners Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation Navigation Welcome Enter Username  Password Username Password CAPSLOCK key turned on security reasons please exit web browser done accessing service require authentication WARNING NOTICE system restricted solely Johnson  Johnson user authorized business only actual attempted unauthorized access use modification system strictly prohibited Johnson  Johnson Unauthorized user subject Johnson  Johnson disciplinary proceeding andor criminal civil penalty state federal applicable domestic foreign laws use system may monitored recorded administrative security reasons monitoring andor recording reveal possible evidence criminal activity Johnson  Johnson may provide evidence monitoring law enforcement officials site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated March  Navigation Home Accelerated realworld data analysis evidence sharing Federated network connectivity data always stay local HONEUR Treating patient haematological malignancy ha progressed significantly recent years extensive scientific research still needed Fortunately huge untapped resource help RealWorld Data RWD Janssen believe RWD ha transformational potential help u develop new tool evidencebased therapies evolve diseasecentred patientcentred model healthcare widespread acceptance usage RWD one key driver moving valuebased healthcare system Valuebased healthcare seek better population health outcome improved patient experiences promoting sustainability increased efficiency reduced health spending overall Better collaboration key unlocking RWDs potential uniting data partners leveraging complementary strengths standardising data common data model end HONEUR Haematological Outcomes Network Europe wa created increase knowledge understanding haematological malignancy improve outcome patient across Europe invite join HONEUR become part federated network collaborating unlock transformational potential RealWorld Data RWD Together help create faster efficient European research environment better share manages RealWorld Evidence RWE generated RWD mission HONEUR created secure collaborative platform enables partnering data centre across Europe including Janssen liberate transformational potential RealWorld Evidence approach use holistic approach combining technology data science able analyse data hospitals registry sources Welcome HONEUR HONEUR PHDENPR Data partner benefit Collaboration full data control data always stay local Strengthened ability perform high quality research part federated network Compensation effort based Fair Market Value Increased data value via expanded authorship publication possibility sponsored study Access  data set patient MMCLLAML Participation network pioneering data management analysis Improved understanding patient treated real world ITEM CODE RF  DATE PREPARATION JANUARY  HONEUR Network Data Partners Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation Data partner HONEUR data partner Czech Republic  CLLEAR Chronic lymphocytic leukemia CLL patient registry CLLEAR registry hosted Czech CLL Study Group Czech Leukemia Study group collect deep insight medical record CLL patient  Czech Republic hospital centers Website Czech Republic  RMG Registry Monoclonal Gammopathies RMG established Czech Myeloma Study Group CMG registry designed collection clinical data  CZ SK Hematology center concerning diagnosis treatment treatment result survival patient MGUS MM SMM Website France  CHU Dijon Bourgogne University Hospital Center Dijon Bourgogne large center offer public emergency service diagnosis care prevention CHU Dijon wellestablihed provision firstclass comprehensive hematological malignancy treatment center Burgundy region ha capability provide heavy therapy treatment certain blood diseases Website France  CHU Lille nearly  professional made  establishments Lille University Hospital Center one largest public health establishment Northern Europe CHU Lille committed scientific excellence service innovation progress transformation practice organizations focus various research areas including cancer research Website France  CHU Montpellier CHU Montpellier French University hospital center focused care teaching research also prevention health education fight social exclusion organized around  university hospital center grouping medical surgical specialty spread several geographical site northeast Montpellier Website France  CHU de Nice hematology department CHU Nice specializes management blood lymph node disorders including cancers develops recourse activity allogeneic autologous hematopoietic stem cell transplantation intensive chemotherapy clinical research allowing access innovative treatments France  MyelomatoulOncopole Toulouse IUCT Oncopole comprises Institut Claudius Regaud cancer center several team Toulouse University Hospital Center two institution offer expertise  professional specialized oncology site site specializes variety rare complex diseases including haematological cancers ha large medical database various blood cancers Website Germany  iOMEDICO iOMEDICO German clinical research institute clinical research organization work large intersectoral network hospital private clinic Germany specializes interventional realworld data study oncology hematology HONEUR work two iOMEDICOs registry platform predominantly collect longitudinal data myeloma lymphoma patients Website Germany  MVZentrum fr Onkologie und Hmatologie Since wa founded  Oncology Sachsenring ha built close network cooperation partner study center oncologist MVZ Study Center Cologne committed holistic treatment malignant disease therefore primary contact aspect cancer spirit holistic care Oncology Cologne therefore developed additional offers include social counseling psychosocial care nutritional therapy sport offer others Furthermore oncology Cologne work closely various tumor conference several hospital allimportant specialist disciplines Website Germany  TriNetX Oncology GmbH TriNetX Oncology GmbH collaborates renowned medical expert pharmaceutical leader generate fitforpurpose database specification match desired study objective scoping oncology rare disease indications gathering complete representative highquality data TherapyMonitor reflects variety cancer care across continent Website Germany  Uniklinikum Wrzburg University Hospital Wrzburg pioneer medical care research teaching hematology department researchoriented focus development new therapeutic approaches Multiple Myeloma sstudy group consists  patients partiuclarly strong Multiple Myeloma research Website Italy  ASST Ovest Milanese Hospital Healthcare company Ovest Milanese public organization includes  entity area near Milan Division Hematology placed new Hospital Legnano count group expert wellproven track record variety oncohaematological disease myeloma lymphomas leukemia collaborates within national international network actively participates research project trial mainly lymphoma myelomas Italy  Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico Hematology department Ospedale Maggiore Policlinico Milan specialises clinical management benign malignant hematology disorders Within largest public research hospital Italy hematology department performs basic translational clinical research myeloma myeloid lymphoid malignancies special focus disease pathogenesis genomic predictor clinical outcomes Italy  IRST Meldola Romagnolo Institute Study Tumors Dino Amadori  IRST center excellence entirely dedicated treatment research training oncology field Since inauguration  IRST IRCCS ha broken new ground multiple area cancer research clinical research programs highlevel training education initiatives center ha strong interest hematological research collect medical patient record variety blood cancers Website Kazakhstan  Kazakh Institute Oncology Radiology Kazakh Research Institute Oncology  Radiology responsible cancer control program Kazakhstan institute provides multidisciplinary approach cancer treatment education training play big role cancer policy Kazakhstan Website Spain  Fundaci Institut Hospital Del Mar dInvestigacions Mdiques IMIM IMIM Hospital del Mar Medical Research Institute researchfocused institute consists  research groups two specifically focused haematological lymphoid myeloid research collect patient data variety haematological malignancies predominant focus lymphomas hospital one biggest site Spain eHealth research also actively contributing project EHDEN HARMONY Website Spain  Instituto de Investigacin Sanitaria IIS La Fe Health Research Institute Hospital La Fe public sector initiative made  entity within Valencia region Hematology Research Group ha wellproven track record collaborates variety national international partner especially leukemia research projects Website Spain  Fundacin Instituto de Investigacin Sanitaria IIS Aragn Lozano Blesa University Hospital part IIS Aragn Health Research Institute Health Department Aragn regional Government Lozano Blesa Hematology Study Group focus hematoncology malignancy iomunotherapy translational lymphoma research Website Spain  Hospital Universitario  Octubre Research Institute Hospital  de Octubre conceived functional structure multidisciplinary translational biomedical research focused basic clinical epidemiological health service research Website Israel  Tel Aviv Sourasky Medical Centre Ichilov Hospital Tel Aviv Sourasky Medical Centers division hematology provides expert care patient variety blood disorders including malignant hematological disease acute chronic leukemias MDS myelodysplastic syndromes multiple myeloma Hodgkins nonHodgkins lymphoma affiliated Sackler Faculty Medicine Tel Aviv University leadingedge scientific clinical research ongoing medical education Website UK  Cancer Centre London Cancer Centre London CCL forefront innovative cancer care recognised Centre Excellence centre ha wellestablished HaematoOncology Unit treat wide range haematological disorders including leukemia lymphoma myeloma Website UK  University Hospitals Leicester NHS University Hospitals Leicester NHS one biggest busiest NHS Trusts country work many different organisation throughout world push boundary research deliver wide range Cancer Haematology National Institute Health Research NIHR study part Myeloma UK Clinical Trials Network Website UK  Cardiff Vale University Health Board Cardiff Vale University Health Board includes University Hospital Wales ha strong link Cardiff University UHW large  bed teaching hospital capital city Wales provides haematological cancer care surrounding population UHW ha strong track record clinical trial routine NHS care Website ITEM CODE RF  DATE PREPARATION NOVEMBER  ITEM CODE RF  DATE PREPARATION  FEBRUARY  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation HONEURs crossfunctional team HONEURs crossfunctional team EXECUTIVE SPONSOR Martin Price PhD Outcomes Research Vice President Health Economics Outcomes Research Reimbursement EMEA Executive Sponsor STEERING COMMITTEE Edmond Chan MDRes MSc MBChB Senior Director EMEA Therapeutic Area Lead Hemato Oncology Kaat Van de Keer MSc Law LLM Legal Director Joris Diels MSc Economics Head Market Access Analysis Health Economics Modelling Tomislav Kamenski PhD Biochemistry Senior Director EMEA Therapy Area Market Access Leader Hematology HONEUR CORE TEAM Kristina Bardenheuer MSc Epidemiology Project Lead HONEUR Michel Van Speybroeck MSc Bioengineering Director Data Science Wout Vekemans MSc Computer Science Product Manager HONEUR Cristian Benza MD Medical Affairs Director Solenn Salaun MSc Management Sciences Project Manager MEDICAL AFFAIRS TEAM Traugott Gruppe MD PhD Regional Medical Affairs Director HaematoOncology EMEA Mark Graham PhD Cardiology EMEA Medical Director early portfolio Claire Albrecht MSc Business Management Medical Affairs Director EMEA MM Christoph Tapprich MD Haematologist Medical Affairs Director EMEA CLL NHL SUBJECT MATTER EXPERTS Dries Van Briel MSc Law LLM Legal Counsel Nolen Perualila PhD Statistics HTA Analyitcs Head Methods Andrada Tatar MD PhD Health Care Compliance Senior Manager Yulia Ramodina MSc Law Privacy Compliance Manager EMEA ITEM CODE RF  DATE PREPARATION JANUARI  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation data partner saying data partner saying Building tradition high quality standard excellence research  de Octubre University Hospital committed collaborating initiative offer best chance success confident becoming member HONEUR network enable u maximise value Multiple Myeloma data may ultimately improve healthcare patients Dr Agustn Gmez de la Cmara Head Clinical Epidemiological Research Health Research Institute  de Octubre University Hospital Madrid Spain My colleague Leicester Royal Infirmary passionate development use database record haematological disorders provide source invaluable information benchmarking education research purposes Joining HONEUR brings u big step closer generating RealWorld Data ultimately ha meaningful impact patients Dr Mamta Garg Consultant Haematologist MD FRCP FRCPath Leicester Royal Infirmary United Kingdom Our registry currently includes different haematological malignancy much looking forward collaborating Janssen HONEUR members make significant inroad improving treatment patient rare blood diseases Prof MUDr Roman Hjek CSc Haematology Registry Monoclonal Gammopathies RMG Czech Republic iOMEDICO ha pioneer field RealWorld Data vision improve oncology refining RWD methodology analysis standards HONEUR offer unique chance collaborate European researcher maintaining integrity security independence databases Dr Norbert Marschner Medical Oncologist CEO iOMEDICO Ever since foundation OIs ha partnering Janssen strive establish realworld evidence crucial source cancer research proud support HONEUR research network data large granular Multiple Myeloma Database Europe Joining force leading hematologists Janssens team expert research organizations excited generate significant current collaborative insight contributing development multiple myeloma treatments Lenka Kellermann Founder Owner OncologyInformationService  CancerDataNet Freiburg Germany ITEM CODE CP  DATE PREPARATION JUNE  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation HONEUR material HONEUR material HONEUR Brochure ITEM CODE CP Join HONEUR ITEM CODE CP Learn six way SAM  Learn help optimise clinical management patients ITEM CODE CP  DATE PREPARATION SEPTEMBER  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation work work shown below data partner example ha application place interrogate data execute analysis script developed centrally HONEUR data partners Individual site physically connected central platform other aggregated result shared securely HONEUR portal shown below Data partner choose initiate question participate or not posed data partners data harmonised OMOP common data model ITEM CODE CP  DATE PREPARATION SEPTEMBER  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation Core principle Core principle HONEUR optimises RealWorld Data analysed speedup generation RealWorld Evidence HONEUR data partner share realworld insight contribute improved patient outcome HONEUR ensures data partner keep full control data time HONEUR respect individual right follows local process regulations eg FAIR GDPR HONEUR increase value data enabling reuse across wide range research study encourages publishing result ITEM CODE CP  DATE PREPARATION SEPTEMBER  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation Research question Research question Data partner choose initiate question participate or not posed data partners examples HONEUR evolves answer question follow overall survival patient relapsed andor refractory multiple myeloma received least three prior line therapy including proteasome inhibitors immunomodulatory IMiD drugs CD monoclonal antibody treatment time next treatment disease progression longterm overall survival year period real world vs predicted overall survival data clinical trials treatment sequence different country associated outcomes eg overall survival Multiple Myeloma Cells ITEM CODE CP  DATE PREPARATION SEPTEMBER  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation become HONEUR data partner become HONEUR data partner HONEURs goal develop network diverse geographic coverage across EuropeAny registry hospital physician association scientific institute patientlevel data following disease become data partner Multiple Myeloma MM Chronic Lymphocytic Leukaemia CLL Diffuse Large BCell Lymphoma DLBCL Myelodysplastic Syndrome MDS Acute Myeloid Leukaemia AML Mantle Cell Lymphoma MCL Follicular Lymphoma FL Marginal Zone Lymphoma MZL ALAmyloidosis benefit network participation fulfil following prerequisites Patientlevel data comprehensive individual patient history Disease characteristic confirmed diagnosis date diagnosis Patient baseline characteristic year birth gender Medications line treatment startstop date Outcomes time next treatment last followup death step join HONEUR   Meeting phone person QA provide information  Data profiling determine structure no access patient data  Signing Access Agreement  Data transformation use HONEUR technical functionality  Access HONEUR portal ready participateinitiate research question Timelines onboarding process vary initial data profiling a process evaluates data structure patientlevel data signing Access Agreement take  months Subsequently data transformation may take  months access HONEUR portal initiateparticipate research questions  joint effort data partner Janssen data transformed OMOP common data model wa developed scientific community  ITEM CODE CP  DATE PREPARATION SEPTEMBER  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation investment real world data investment real world data compensation based Fair Market Value FMV consists three pillars SET REMUNERATION join network compensate ITbased efforts Remuneration dependent data modelorganisational complexity effort needed implement HONEUR site FEASIBILITY QUERIES grant annual remuneration participate feasibility queries TAKING PART RESEARCH QUESTIONS Remuneration dependent data volume quality complexity analysis calculated start study Blast cell Acute Myeloid Leukemia ITEM CODE CP  DATE PREPARATION SEPTEMBER  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation Join network Join network registry hospital physician association scientific institute data set patient fulfills certain become data partner learn become data partner enroll data partner accordance comply legal obligations ITEM CODE CP  DATE PREPARATION SEPTEMBER  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation Contact Contact general information Kristina Bardenheuer Project Lead T technical information Michel Van Speybroeck Data Science Director T Request Access request creation deactivation user accounts please fill following PDF Sign PDF send ITEM CODE CP  DATE PREPARATION SEPTEMBER  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation News News  delighted introduce th HONEUR data partner ASST Ovest Milanese Hospital Healthcare company Ovest Milanese public organization include  entity area near   shared  Winter HONEUR Newsletter edition features  HONEUR data partners CHU Nice Policlinico di Milano newest members  collaboration HONEUR Data partner Cancer Centre London published abstract Blood entitled Honeur Framework Generating Computer Understandable Cohort Definitions Clinical Trial Protoco  Thrilled share news upcoming fourth HONEUR Forum meeting picturesque city Rome Italy March   Calling upon esteemed HONEUR Data Partners potential collaborator part   HONEUR Summer Newsletter ha sent out edition find update ongoing planned evidencegeneration projects recap recent HONEUR Forum meeting Amsterdam ex ITEM CODE RF  DATE PREPARATION NOVEMBER  ITEM CODE RF  DATE PREPARATION  JUNE  ITEM CODE RF  DATE PREPARATION  FEBRUARY  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation FAQ FAQs HONEUR HONEUR Haematology Outcomes Network Europe Janssenled initiative collaboration Rather creating central data repository HONEUR federated data network enables partner keep full control data analysis bringing together data centre Europe scale research haematological malignancies aspires create future patient haematological malignancy across Europe improved outcome power RealWorld Data RealWorld Evidence maximised scope HONEUR HONEUR platform designed connect network data source across Europe data patient haematological malignancies Data always stay protected network partner keep control data times Data partner able use new tool securely analyse large volume data European scale facilitate generation new RealWorld Evidence haematological malignancies eg possibletrajectories biological marker cancer type severity effectiveness different treatments RealWorld Data RWD RealWorld Evidence RWE Innovative Medicines Initiative IMI definitions RealWorld Data RWD umbrella term data regarding effect health intervention eg benefit risk resource use collected context conventional randomised clinical trial RCTs RWD obtained many source including patient registries electronic medical records observational studies RealWorld Evidence RWE evidence derived analysis andor synthesis RWD RWD important RWD different clinical trial data offer broader diversity patient could develop haematological malignancies reflects wide variation disease like cancer diagnosed treated usually span full disease history diagnosis longterm survival death include information condition treated parallel cancer treatment may interact summary RWD complement result randomised clinical trial expands knowledge treatment outcome real world deepens understanding disease epidemiology impact patient public health also provides insight improved patient care benefit future research type question answered HONEUR power HONEUR lie enabling data analysis multiple data set methodological statistical possibilities analysing data multiple partners common research question overall survival time next treatment treatment sequencing answered example  HONEUR evolves answer question follow information stored HONEUR data portal HONEUR portal core network secured environment accessible HONEUR partners offer different functionality partners data catalogue contains description various data set data partner engage them study catalogue central place study request get initiated analysis script eventually aggregated result stored visible study participant only patientlevel data stored HONEUR portal aggregated result research question data secured patient privacy protected HONEUR network based principle data partner local governance keep control data times original source data transformed data partner site OMOPcommon data model always stay local data partner agrees participate analysis would carried locally result would posted central HONEUR portal base case result aggregated seldomseen case research question answered patientlevel data and upon explicit agreement pseudonymised data shared data always protected encryption remuneration covered Janssen Janssen remunerates Fair Market Valuefor effort arising implementation HONEUR setup phase well research question carried out Additionally Janssen pay yearly fee performed feasibility queries Didnt find answer question here Feel free enroll data partner accordance comply legal obligations ITEM CODE CP  DATE PREPARATION SEPTEMBER  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation Privacy policy Privacy policy Janssen Phamaceutica NV care privacy want familiar collect use disclose information Privacy Policy describes practice connection information service provider collect website application hereinafter Service operated controlled u accessing Privacy Policy providing personal information u using Service acknowledge read understand Privacy Policy USE MINORS Service directed individual age of request individual provide personal information Service child ha submitted Personal Information would like request Personal Information removed please contact u explained Contacting Us INFORMATION COLLECTION may ask submit personal information order benefit certain feature such newsletter subscriptions tipspointers order processing participate particular activity such sweepstakes promotions informed information required information optional may combine information submit information collected you whether offline including example purchase history may also combine information receive Johnson  Johnson affiliate submit personal information relating another individual us represent authority permit u use information accordance Privacy Policy SENSITIVE INFORMATION Unless specifically request invite it ask send us disclose sensitive personal information eg Social Security numbers information related racial ethnic origin political opinions religion philosophical beliefs health medical conditions sex life sexual orientation criminal background trade union membership biometric genetic data Service otherwise us AUTOMATIC INFORMATION COLLECTION USE service provider may collect certain information automatically navigate around Service Please read detailed information cooky tracking technology used Service Except allowed applicable law place cooky received consent cookie banner preference center Cookie Policy includes information may disable technologies service provider may also automatically collect use information following ways browser Certain information collected browsers Media Access Control MAC address computer type Windows Mac screen resolution operating system name version Internet browser type version may collect similar information device type identifier access Service mobile device use information ensure Service function properly IP address IP address number automatically assigned computer Internet Service Provider IP address identified logged automatically server log file whenever user visit Service along time visit page visited Collecting IP address standard practice done automatically many online services use IP address purpose calculating Service usage levels diagnosing server problems administering Service may also derive approximate location IP address Device Information may collect information mobile device unique device identifier understand use Service USE DISCLOSE INFORMATION use disclose information provide u described point collection Please see section entitled Choices Access below learn may opt certain us disclosures required applicable law obtain consent use personal information point information collection may also use information necessary perform contract comply legal obligation for example due pharmacovigilance obligations legitimate business interests may also rely legal bases specifically for Providing functionality Service fulfilling requests provide functionality Service providing related customer service respond inquiry fulfill requests send document request email alerts send important information regarding relationship regarding Service change terms conditions policy andor administrative information engage activity manage contractual relationship andor comply legal obligation Accomplishing business purposes data analysis example improve efficiency Service audits verify internal process function intended compliant legal regulatory contractual requirements fraud security monitoring purposes example detect prevent cyberattacks attempt commit identity theft developing new product services enhancing improving modifying website product services identifying Service usage trends example understanding part Service interest users determining effectiveness promotional campaigns adapt campaign need interest users engage activity manage contractual relationship you comply legal obligation andor legitimate interest Analysis Personal Information provide personalized services better understand you personalize interaction provide information andor offer tailored interests better understand preference deliver content via Service believe relevant interesting you provide personalized service either consent legitimate interest also disclose information collected Service affiliate purpose described Privacy Policy list affiliate available click link Form K Exhibit  SEC Filings Janssen Pharamceutica NV party responsible management jointlyused Personal Information third party partner offer cobranded comarketed promotion third party service provider provide service website hosting moderating mobile application hosting data analysis payment processing order fulfillment infrastructure provision services customer service email direct mail delivery services auditing services order enable provide services permitted applicable law third party event reorganization merger sale joint venture assignment transfer disposition portion business assets stock including connection bankruptcy similar proceedings addition may use disclose information believe necessary appropriate a comply legal process applicable law may include law outside country residence b permitted applicable law respond request public government authorities may include authority outside country residence c enforce term conditions d protect rights privacy safety property andor affiliates you others may also use disclose information way obtaining consent so may use disclose information collect automatically described above Automatic Information Collection Use addition allowed applicable law may use disclose information personally identifiable form purpose combine information personally identifiable form information identifiable such combining name geographical location treat combined information personal information long combined CHOICES ACCESS choice regarding use disclosure personal information give choice regarding use disclosure personal information marketing purposes may opt from Receiving marketing communication us longer want receive marketing communication u goingforward basis may opt receiving contacting u via  request us please provide name identify forms marketing communication longer wish receive include addresses itthey sent example longer wish receive marketing email direct mail us tell u that provide name email postal addressYou may also opt receiving marketing communication u visiting Service update online profile addition may opt receiving marketing email u following unsubscribe instruction provided message Receiving reminder us longer want receive medical reminder u goingforward basis may opt receiving contacting u via response us please provide name email address phone number receive reminder us sharing personal information affiliate thirdparty partners previously optedin receiving marketing communication affiliate third party partners may opt sharing personal information party direct marketing purpose goingforward basis contacting u viaIn communication us please state longer share personal information affiliate andor thirdparty partner marketing purposes include name email address seek comply requests soon reasonably practicable Please note opt described above able remove personal information database affiliate already shared information ie date implement optout request However make reasonable effort inform affiliate request Please also note opt receiving marketingrelated message us may still send important transactional administrative messages cannot opt out access change delete personal information would like review correct update restrict delete personal information would like request electronic copy personal information purpose transmitting another company to extent right provided applicable law please contact u via respond request soon reasonably practicable later one month receipt circumstance cause delay response promptly notified provided date response CROSSBORDER TRANSFER personal information may stored processed country facility service providers using Service providing consent u where required law information may transferred country outside country residence including United States may provide different data protection rule country Nonetheless appropriate contractual measure place protect personal information transferred affiliate third party countries nonEuropean Economic Area EEA country recognized European Commission providing adequate level data protection according EEA standard the full list country available transfer EEA country considered adequate European Commission ensured adequate measure place including ensuring recipient bound byEU Standard Contractual Clauses protect Personal Information may obtain copy measure contacting data protection officer accordance Contacting Us section below SECURITY seek use reasonable organizational technical administrative measure designed protect personal information control Unfortunately data transmission Internet data storage system guaranteed  secure reason believe interaction u longer secure for example feel security account u ha compromised please immediately notify u accordance Contacting Us section below RETENTION PERIOD retain personal information long needed permitted light purposes wa obtained criterion used determine retention period include i length time ongoing relationship provide Service you ii whether legal obligation subject iii whether retention advisable light legal position such regard applicable statute limitations litigation regulatory investigations Please note however exhaustive list retention periods personal information may stored longer period using criterion set forth first paragraph section especially point ii iii THIRD PARTY SITES SERVICES Service may contain link site third parties Privacy Policy doe address responsible for privacy information practice third parties including third party operating site online service including without limitation application available Service Service contains link availability of inclusion link to site property Service doe imply endorsement u affiliates CONTACTING US JanssenCilag Limited located  Holmers Farm Way High Wycombe Buckinghamshire HP EGis company responsible collection use disclosure personal information Privacy Policy question Privacy Policy please contact u via please write following address Janssen Pharmaceutica NV Att Honeur Network Turnhoutseweg   Beerse Belgium may also contact data protection officer responsible country region applicable at LODGING COMPLAINT REGULATOR may lodge complaint supervisory authority competent country regionPlease click contact information authorities UPDATES PRIVACY POLICY may change Privacy Policy change Privacy Policy become effective post revised Privacy Policy Service use Service following change mean accept revised Privacy Policy recommend regularly review Privacy Policy visit Service policy wa last updated on ITEM CODE CP  DATE PREPARATION SEPTEMBER  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation Legal notice Legal notice content Internet site owned controlled Janssen Pharmaceutica NV protected worldwide copyright laws may download content personal use noncommercial purpose modification reproduction content permitted content may otherwise copied used way owner site use reasonable effort include uptodate accurate information Internet site make representations warranties assurance accuracy currency completeness information provided owner site shall liable damage injury resulting access to inability access Internet site reliance information provided Internet site site internet audience Europe Middle East Africa Albania Algeria Andorra Armenia Austria Bahrain Belgium Bosnia Herzegovina Bulgaria Croatia Cyprus Czech Republic Denmark Egypt Estonia Faroe Islands Finland France Georgia Germany Ghana Gibraltar Greece Hungary Iceland Iraq Ireland Israel Italy Jordan Kuwait Latvia Lebanon Libya Lithuania Luxembourg Macedonia Malta Monaco Netherlands Nigeria Norway Oman Poland Portugal Qatar Romania Russia San Marino Saudi Arabia Serbia Sierra Leone Slovakia Slovenia South Africa Spain Sweden Switzerland Turkey Ukraine United Arab Emirates United Kingdom Yemen Internet site may provide link reference site owner site responsibility content site shall liable damage injury arising content link site provided merely convenience user Internet site trademarks service marks trade names trade dress product Internet site protected Europe Middle East Africa use may made without prior written authorization owner site except identify product service company personally identifiable information electronic communication Internet site governed sites  owner site shall free use copy information communications including ideas inventions concepts technique knowhow disclosed therein purposes purpose may include disclosure third party andor developing manufacturing andor marketing good services sender communication Internet site otherwise owner site shall responsible content information contained therein including truthfulness accuracy Internet site provided service visitors site owner reserve right delete modify supplement content site time reason without notification ITEM CODE CP  DATE PREPARATION SEPTEMBER  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January  Navigation Cookie policy Cookie policy Cookie Policy designed tell practice regarding collection information cooky tracking technology like gifs web beacons etc functionality use technology may include following Assisting navigation Assisting registering events login ability provide feedback Analyzing use products service applications Assisting promotional marketing effort including behavioral advertising Offering content third party such social medium content detailed list cooky use description classify cooky following categories Strictly Necessary Cookies Performance Cookies Functional Cookies Targeting Cookies Except allowed applicable law place cooky received consent cookie banner preference center change cookie setting per cookie category except strictly necessary cooky required proper functioning site time clicking cookie setting button below Cookie Settings Links website site may contain link reference websites Please aware control cooky  tracking technology website Cookie Policy doe apply websites Contact Us questions comments concern Cookie Policy information practice site please use contact information included Privacy Policy Changes Cookie Policy Cookie Policy changes revised policy posted site Cookie Policy wa last updated may  ITEM CODE CP  DATE PREPARATION SEPTEMBER  Hidden Follow site published Janssen Pharmaceutica NV solely responsible content site intended use visitor Europe Middle East Africa Last Updated January 